Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 37 | 2020 | 2161 | 4.630 |
Why?
|
| Transcranial Direct Current Stimulation | 7 | 2018 | 111 | 3.650 |
Why?
|
| Stroke Rehabilitation | 8 | 2019 | 334 | 2.910 |
Why?
|
| Recovery of Function | 11 | 2018 | 506 | 2.310 |
Why?
|
| Brain Ischemia | 13 | 2018 | 665 | 1.900 |
Why?
|
| Upper Extremity | 4 | 2017 | 112 | 1.270 |
Why?
|
| Motor Cortex | 2 | 2018 | 158 | 1.110 |
Why?
|
| Brain | 8 | 2017 | 2175 | 1.100 |
Why?
|
| Pyramidal Tracts | 4 | 2017 | 45 | 1.020 |
Why?
|
| Fibrinolytic Agents | 3 | 2017 | 377 | 0.870 |
Why?
|
| Tyrosine | 3 | 2017 | 196 | 0.840 |
Why?
|
| Functional Laterality | 4 | 2017 | 240 | 0.830 |
Why?
|
| Carotid Stenosis | 3 | 2017 | 163 | 0.820 |
Why?
|
| Ischemic Preconditioning | 3 | 2018 | 31 | 0.820 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2016 | 296 | 0.780 |
Why?
|
| Ischemic Attack, Transient | 2 | 2018 | 167 | 0.710 |
Why?
|
| Wearable Electronic Devices | 1 | 2019 | 16 | 0.700 |
Why?
|
| Humans | 50 | 2020 | 68525 | 0.670 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 71 | 0.670 |
Why?
|
| Cerebrovascular Disorders | 2 | 2017 | 182 | 0.650 |
Why?
|
| Berberine | 1 | 2018 | 3 | 0.650 |
Why?
|
| Curcumin | 1 | 2018 | 23 | 0.640 |
Why?
|
| Evoked Potentials, Motor | 1 | 2018 | 63 | 0.640 |
Why?
|
| Brain Waves | 1 | 2018 | 30 | 0.630 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2017 | 239 | 0.630 |
Why?
|
| Electromagnetic Fields | 1 | 2018 | 66 | 0.630 |
Why?
|
| Thalamus | 1 | 2018 | 82 | 0.620 |
Why?
|
| Lovastatin | 1 | 2018 | 78 | 0.620 |
Why?
|
| Treatment Outcome | 18 | 2020 | 7028 | 0.610 |
Why?
|
| Aged | 23 | 2020 | 14842 | 0.610 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 87 | 0.590 |
Why?
|
| Biological Products | 1 | 2018 | 78 | 0.580 |
Why?
|
| Movement Disorders | 1 | 2017 | 58 | 0.580 |
Why?
|
| Ultrasonography | 2 | 2017 | 453 | 0.570 |
Why?
|
| Male | 32 | 2020 | 37281 | 0.560 |
Why?
|
| Female | 32 | 2020 | 38015 | 0.550 |
Why?
|
| Hepatic Artery | 1 | 2015 | 25 | 0.550 |
Why?
|
| Thrombectomy | 4 | 2020 | 238 | 0.550 |
Why?
|
| Middle Aged | 26 | 2020 | 21119 | 0.550 |
Why?
|
| Vasoconstriction | 1 | 2015 | 81 | 0.540 |
Why?
|
| Atherosclerosis | 1 | 2017 | 204 | 0.530 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2015 | 17 | 0.520 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 22 | 0.520 |
Why?
|
| Memory, Short-Term | 1 | 2015 | 79 | 0.510 |
Why?
|
| Severity of Illness Index | 4 | 2016 | 1851 | 0.510 |
Why?
|
| Neuronal Plasticity | 1 | 2017 | 274 | 0.500 |
Why?
|
| Time Factors | 10 | 2017 | 4655 | 0.500 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2014 | 4 | 0.490 |
Why?
|
| Antihypertensive Agents | 3 | 2015 | 497 | 0.480 |
Why?
|
| Optic Nerve Diseases | 1 | 2014 | 31 | 0.480 |
Why?
|
| Demyelinating Diseases | 1 | 2014 | 57 | 0.480 |
Why?
|
| Hospitalization | 5 | 2014 | 977 | 0.470 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.470 |
Why?
|
| Hypertension | 4 | 2016 | 1531 | 0.450 |
Why?
|
| Thrombolytic Therapy | 2 | 2016 | 233 | 0.450 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2010 | 21 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 2222 | 0.430 |
Why?
|
| Blood Pressure | 2 | 2015 | 1447 | 0.400 |
Why?
|
| Cognition | 1 | 2015 | 512 | 0.390 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 693 | 0.360 |
Why?
|
| Neurosyphilis | 1 | 2009 | 7 | 0.360 |
Why?
|
| Disability Evaluation | 3 | 2017 | 298 | 0.340 |
Why?
|
| Aged, 80 and over | 10 | 2018 | 4843 | 0.340 |
Why?
|
| Animals | 8 | 2018 | 20877 | 0.320 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2013 | 413 | 0.320 |
Why?
|
| Quality of Life | 2 | 2015 | 1515 | 0.300 |
Why?
|
| Anisotropy | 2 | 2017 | 105 | 0.290 |
Why?
|
| Aspirin | 2 | 2018 | 295 | 0.270 |
Why?
|
| Patient Discharge | 4 | 2019 | 294 | 0.270 |
Why?
|
| Myocardial Infarction | 2 | 2016 | 807 | 0.270 |
Why?
|
| Adult | 10 | 2018 | 21375 | 0.270 |
Why?
|
| Recurrence | 4 | 2018 | 948 | 0.270 |
Why?
|
| Peroneal Nerve | 2 | 2015 | 6 | 0.250 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 373 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2019 | 3702 | 0.250 |
Why?
|
| Retrospective Studies | 8 | 2020 | 7264 | 0.250 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 1465 | 0.240 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1737 | 0.230 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2015 | 86 | 0.230 |
Why?
|
| Electric Stimulation Therapy | 2 | 2015 | 147 | 0.220 |
Why?
|
| Length of Stay | 2 | 2019 | 780 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 3256 | 0.200 |
Why?
|
| Adolescent | 5 | 2018 | 8903 | 0.200 |
Why?
|
| Developed Countries | 2 | 2017 | 8 | 0.190 |
Why?
|
| Risk Factors | 6 | 2017 | 5719 | 0.180 |
Why?
|
| Wrist | 1 | 2019 | 24 | 0.180 |
Why?
|
| Vibration | 1 | 2019 | 32 | 0.180 |
Why?
|
| Physical Stimulation | 1 | 2019 | 67 | 0.170 |
Why?
|
| Developing Countries | 2 | 2017 | 106 | 0.170 |
Why?
|
| Safety | 1 | 2019 | 145 | 0.170 |
Why?
|
| Cerebral Angiography | 2 | 2017 | 151 | 0.170 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 11 | 0.160 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 71 | 0.160 |
Why?
|
| Information Systems | 1 | 2018 | 45 | 0.160 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 87 | 0.160 |
Why?
|
| Medical Futility | 1 | 2018 | 31 | 0.160 |
Why?
|
| Sample Size | 1 | 2018 | 79 | 0.160 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 137 | 0.160 |
Why?
|
| Blood Glucose | 2 | 2018 | 631 | 0.150 |
Why?
|
| Organ Size | 1 | 2018 | 242 | 0.150 |
Why?
|
| Disease Progression | 2 | 2017 | 1037 | 0.150 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1054 | 0.150 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 45 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 186 | 0.150 |
Why?
|
| Corpus Callosum | 1 | 2016 | 29 | 0.150 |
Why?
|
| Hypolipidemic Agents | 1 | 2017 | 82 | 0.140 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 54 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 122 | 0.140 |
Why?
|
| Carotid Artery Diseases | 1 | 2017 | 83 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 291 | 0.140 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 133 | 0.140 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 161 | 0.140 |
Why?
|
| Ticlopidine | 1 | 2016 | 118 | 0.140 |
Why?
|
| Polygonaceae | 1 | 2016 | 1 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 298 | 0.140 |
Why?
|
| Glucosides | 1 | 2016 | 16 | 0.140 |
Why?
|
| Brain Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Axons | 1 | 2017 | 139 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 648 | 0.140 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2016 | 15 | 0.140 |
Why?
|
| Ions | 1 | 2016 | 50 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2323 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2017 | 296 | 0.140 |
Why?
|
| Body Weight | 1 | 2018 | 554 | 0.140 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 455 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2018 | 652 | 0.140 |
Why?
|
| Income | 1 | 2016 | 165 | 0.140 |
Why?
|
| Pneumonia | 1 | 2016 | 110 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2017 | 737 | 0.140 |
Why?
|
| Stilbenes | 1 | 2016 | 57 | 0.130 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 82 | 0.130 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 567 | 0.130 |
Why?
|
| Analysis of Variance | 1 | 2017 | 1039 | 0.130 |
Why?
|
| Metals | 1 | 2016 | 100 | 0.130 |
Why?
|
| South Carolina | 3 | 2014 | 2750 | 0.130 |
Why?
|
| Insulin | 1 | 2018 | 617 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 174 | 0.130 |
Why?
|
| Hemodynamics | 1 | 2017 | 705 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 176 | 0.120 |
Why?
|
| Stents | 2 | 2017 | 657 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 374 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2016 | 241 | 0.120 |
Why?
|
| Antidepressive Agents | 1 | 2015 | 216 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2014 | 51 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.120 |
Why?
|
| Osmosis | 1 | 2014 | 38 | 0.120 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2014 | 37 | 0.120 |
Why?
|
| Malnutrition | 1 | 2014 | 28 | 0.120 |
Why?
|
| Racism | 1 | 2014 | 59 | 0.120 |
Why?
|
| Oxidative Stress | 1 | 2018 | 718 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 848 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 445 | 0.120 |
Why?
|
| Biomarkers | 2 | 2017 | 1593 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 729 | 0.120 |
Why?
|
| Risk | 2 | 2016 | 563 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2014 | 168 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 157 | 0.110 |
Why?
|
| Young Adult | 2 | 2018 | 5708 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 361 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2018 | 2083 | 0.110 |
Why?
|
| Neural Pathways | 1 | 2015 | 323 | 0.110 |
Why?
|
| Infant | 2 | 2010 | 2891 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2010 | 3185 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 1118 | 0.110 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 268 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1293 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2014 | 384 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 3 | 2017 | 198 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 581 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 772 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 438 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 286 | 0.100 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2010 | 20 | 0.090 |
Why?
|
| Glasgow Coma Scale | 1 | 2010 | 65 | 0.090 |
Why?
|
| Mechanical Thrombolysis | 1 | 2010 | 29 | 0.090 |
Why?
|
| Prognosis | 1 | 2015 | 2093 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 378 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 938 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2550 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 334 | 0.090 |
Why?
|
| Rats | 1 | 2017 | 5300 | 0.080 |
Why?
|
| Age Factors | 2 | 2014 | 1860 | 0.080 |
Why?
|
| Telemedicine | 1 | 2017 | 699 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 329 | 0.080 |
Why?
|
| Smoking | 1 | 2016 | 1449 | 0.080 |
Why?
|
| Child | 2 | 2010 | 6400 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.080 |
Why?
|
| Pregnancy | 1 | 2014 | 2331 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2009 | 344 | 0.070 |
Why?
|
| Comorbidity | 1 | 2010 | 1425 | 0.070 |
Why?
|
| International Classification of Diseases | 2 | 2016 | 85 | 0.070 |
Why?
|
| Foot Orthoses | 2 | 2015 | 7 | 0.060 |
Why?
|
| Registries | 2 | 2018 | 730 | 0.060 |
Why?
|
| Ankle | 2 | 2015 | 45 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2010 | 2004 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2009 | 2453 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 929 | 0.050 |
Why?
|
| Incidence | 2 | 2017 | 1582 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2015 | 1329 | 0.040 |
Why?
|
| China | 1 | 2018 | 138 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 38 | 0.040 |
Why?
|
| United States | 1 | 2010 | 7335 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 89 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2017 | 82 | 0.040 |
Why?
|
| Databases, Bibliographic | 1 | 2017 | 14 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 117 | 0.040 |
Why?
|
| Cerebral Peduncle | 1 | 2016 | 1 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 62 | 0.040 |
Why?
|
| Internationality | 1 | 2016 | 74 | 0.040 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 366 | 0.040 |
Why?
|
| Plant Roots | 1 | 2016 | 22 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 125 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 211 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 52 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 61 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 413 | 0.030 |
Why?
|
| Telomere | 1 | 2014 | 59 | 0.030 |
Why?
|
| Foot | 1 | 2014 | 66 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 1046 | 0.030 |
Why?
|
| Health Personnel | 1 | 2016 | 286 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 346 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2014 | 112 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 424 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1139 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 594 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 689 | 0.030 |
Why?
|
| Walking | 1 | 2015 | 240 | 0.030 |
Why?
|
| Brain Stem Infarctions | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2356 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 35 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 39 | 0.020 |
Why?
|
| Basilar Artery | 1 | 2010 | 38 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 237 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 181 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 572 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2673 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 1341 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2017 | 1032 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 2790 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 8472 | 0.010 |
Why?
|